Abstract:Interventions incorporating meditation to address stress, anxiety, and depression, and improve self‐management, are becoming popular for many health conditions. Stress is a risk factor for cardiovascular disease (CVD) and clusters with other modifiable behavioural risk factors, such as smoking. Meditation may therefore be a useful CVD prevention strategy. To determine the effectiveness of meditation, primarily mindfulness‐based interventions (MBIs) and transcendental meditation (TM), for the primary and secondary prevention of CVD. We searched CENTRAL, MEDLINE, Embase, three other databases, and two trials registers on 14 November 2021, together with reference checking, citation searching, and contact with study authors to identify additional studies. We included randomised controlled trials (RCTs) of 12 weeks or more in adults at high risk of CVD and those with established CVD. We explored four comparisons: MBIs versus active comparators (alternative interventions); MBIs versus non‐active comparators (no intervention, wait list, usual care); TM versus active comparators; TM versus non‐active comparators. We used standard Cochrane methods. Our primary outcomes were CVD clinical events (e.g. cardiovascular mortality), blood pressure, measures of psychological distress and well‐being, and adverse events. Secondary outcomes included other CVD risk factors (e.g. blood lipid levels), quality of life, and coping abilities. We used GRADE to assess the certainty of evidence. We included 81 RCTs (6971 participants), with most studies at unclear risk of bias. MBIs versus active comparators (29 RCTs, 2883 participants) Systolic (SBP) and diastolic (DBP) blood pressure were reported in six trials (388 participants) where heterogeneity was considerable (SBP: MD ‐6.08 mmHg, 95% CI ‐12.79 to 0.63, I 2 = 88%; DBP: MD ‐5.18 mmHg, 95% CI ‐10.65 to 0.29, I 2 = 91%; both outcomes based on low‐certainty evidence). There was little or no effect of MBIs on anxiety (SMD ‐0.06 units, 95% CI ‐0.25 to 0.13; I 2 = 0%; 9 trials, 438 participants; moderate‐certainty evidence), or depression (SMD 0.08 units, 95% CI ‐0.08 to 0.24; I 2 = 0%; 11 trials, 595 participants; moderate‐certainty evidence). Perceived stress was reduced with MBIs (SMD ‐0.24 units, 95% CI ‐0.45 to ‐0.03; I 2 = 0%; P = 0.03; 6 trials, 357 participants; moderate‐certainty evidence). There was little to no effect on well‐being (SMD ‐0.18 units, 95% CI ‐0.67 to 0.32; 1 trial, 63 participants; low‐certainty evidence). There was little to no effect on smoking cessation (RR 1.45, 95% CI 0.78 to 2.68; I 2 = 79%; 6 trials, 1087 participants; low‐certainty evidence). None of the trials reported CVD clinical events or adverse events. MBIs versus non‐active comparators (38 RCTs, 2905 participants) Clinical events were reported in one trial (110 participants), providing very low‐certainty evidence (RR 0.94, 95% CI 0.37 to 2.42). SBP and DBP were reduced in nine trials (379 participants) but heterogeneity was substantial (SBP: MD ‐6.62 mmHg, 95% CI ‐13.15 to ‐0.1, I 2 = 87%; DBP: MD ‐3.35 mmHg, 95% CI ‐5.86 to ‐0.85, I 2 = 61%; both outcomes based on low‐certainty evidence). There was low‐certainty evidence of reductions in anxiety (SMD ‐0.78 units, 95% CI ‐1.09 to ‐0.41; I 2 = 61%; 9 trials, 533 participants; low‐certainty evidence), depression (SMD ‐0.66 units, 95% CI ‐0.91 to ‐0.41; I 2 = 67%; 15 trials, 912 participants; low‐certainty evidence) and perceived stress (SMD ‐0.59 units, 95% CI ‐0.89 to ‐0.29; I 2 = 70%; 11 trials, 708 participants; low‐certainty evidence) but heterogeneity was substantial. Well‐being increased (SMD 0.5 units, 95% CI 0.09 to 0.91; I 2 = 47%; 2 trials, 198 participants; moderate‐certainty evidence). There was little to no effect on smoking cessation (RR 1.36, 95% CI 0.86 to 2.13; I 2 = 0%; 2 trials, 453 participants; low‐certainty evidence). One small study (18 participants) reported two adverse events in the MBI group, which were not regarded as serious by the study investigators (RR 5.0, 95% CI 0.27 to 91.52; low‐certainty evidence). No subgroup effects were seen for SBP, DBP, anxiety, depression, or perceived stress by primary and secondary prevention. TM versus active comparators (8 RCTs, 830 participants) Clinical events were reported in one trial (201 participants) based on low‐certainty evidence (RR 0.91, 95% CI 0.56 to 1.49). SBP was reduced (MD ‐2.33 mmHg, 95% CI ‐3.99 to ‐0.68; I 2 = 2%; 8 trials, 774 participants; moderate‐certainty evidence), with an uncertain effect on DBP (MD ‐1.15 mmHg, 95% CI ‐2.85 to 0.55; I 2 = 53%; low‐certainty evidence). There was little or no effect on anxiety (SMD 0.06 units, 95% CI ‐0.22 to 0.33; I 2 = 0%; 3 trials, 200 participants; low‐certainty evidence), depression ( -Abstract Truncated-

Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial

The evolution of subjective cognition after meditation training in older people: a secondary analysis of the three-arm age-well randomized controlled trial

Meditation dosage predicts self- and teacher-perceived responsiveness to an 18-month randomised controlled trial

Effects of meditation on health promoting protective factors of persons with cardiovascular disease-a quasi-experimental pilot study with pre-post comparison

Four weeks of meditation training improves sustained attention in community-dwelling older adults: a proof-of-concept randomized controlled trial

Decoding meditation mechanisms underlying brain preservation and psycho-affective health in older expert meditators and older meditation-naive participants

Impact of mindfulness-based and health self-management interventions on mindfulness, self-compassion, and physical activity in older adults with subjective cognitive decline: A secondary analysis of the SCD-Well randomized controlled trial

Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial

Effects of Meditation versus Music Listening on Perceived Stress, Mood, Sleep, and Quality of Life in Adults with Early Memory Loss: A Pilot Randomized Controlled Trial

Meditation for the primary and secondary prevention of cardiovascular disease

Feasibility of Integrating MEditatioN inTO heaRt Disease (the MENTOR Study): A Phase II Randomized Controlled Trial

Effects of short-term moderate intensity exercise on the serum metabolome in older adults: a pilot randomized controlled trial

The MEDITAGING study: protocol of a two-armed randomized controlled study to compare the effects of the mindfulness-based stress reduction program against a health promotion program in older migrants in Luxembourg

A randomised controlled intervention trial evaluating the efficacy of a Mediterranean dietary pattern on cognitive function and psychological wellbeing in healthy older adults: the MedLey study

FC54: Effects of a mindfulness meditation intervention with neurofeedback on psychological well- being, cognition, and quality of life in older adults experiencing loneliness - a pilot randomized controlled study

Meditation training for people with amyotrophic lateral sclerosis: a randomized clinical trial

Effects of 12 weeks of functional training vs. Muay Thai on cardiac autonomic modulation and hemodynamic parameters in older adults: a randomized clinical trial

The protective role of long-term meditation on the decline of the executive component of attention in aging: a preliminary cross-sectional study

Association between urate-lowering therapies and cognitive decline in community-dwelling older adults

Cognitive Aging and Long-Term Maintenance of Attentional Improvements Following Meditation Training

Pilot Study of Compassion Meditation Training to Improve Well-being Among Older Adults